Wong, Wing-Yan, Chan, Brandon Dow, Sham, Tung-Ting 
ORCID: 0000-0002-9648-4964, Lee, Magnolia Muk-Lan, Chan, Chi-On, Chau, Chung-Ting, Mok, Daniel Kam-Wah, Kwan, Yiu-Wa and Tai, William Chi-Shing
(2022)
<i>Lactobacillus casei</i> Strain Shirota Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice by Increasing Taurine-Conjugated Bile Acids and Inhibiting NF-κB Signaling <i>via</i> Stabilization of Iκ<i>B</i>α.
FRONTIERS IN NUTRITION, 9.
816836-.
|
Text
iLactobacillus caseii Strain Shirota Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice by Increasing Taurine-Conjug.pdf - Published version Download (1MB) | Preview |
Abstract
Inflammatory bowel disease (IBD) is a chronic progressive intestinal inflammatory disease, characterized by an altered gut microbiota composition and accompanying alterations in circulatory bile acids. Increasing evidence supports the beneficial effect of probiotics intake on health. Introduction of probiotics to the intestines can modulate gut microbiota composition and in turn regulate the host immune system and modify the inflammatory response. Probiotics can also improve intestinal barrier function and exhibit a positive impact on host physiological and pathological conditions <i>via</i> gut microbiota-derived metabolites. Previous studies have demonstrated that <i>Lactobacillus casei</i> strain Shirota (LcS) treatment could inhibit clinical manifestation of colitis in dextran sulfate sodium (DSS)-induced mice, however, the underlying mechanisms remain unknown. In this study, we employed the DSS-induced acute colitis mouse model to investigate the anti-inflammatory effects of LcS and related mechanisms. Administration of LcS ameliorated the severity of DSS-induced colitis and enhanced intestinal integrity <i>via</i> induction of mucin-2 and occludin expression in colons. Fecal microbiota analysis showed that LcS increased the relative abundance of beneficial bacterial species in colitic mice, whereas the relative abundance of pathobionts was reduced. Additionally, LcS treatment modulated circulating bile acid profiles in colitic mice. In mice treated with LcS, we identified increased levels of primary taurine-conjugated bile acids, including taurocholic acid (TCA) and taurochenodeoxycholic acid (TCDCA). LcS treatment also increased the levels of secondary taurine-conjugated bile acids, including taurodeoxycholic acid (TDCA) and tauroursodeoxycholic acid (TUDCA). Moreover, LcS treatment exhibited a suppressive effect on the hydroxylated primary bile acids α-muricholic acid (α-MCA) and β-muricholic acid (β-MCA). We further demonstrated that LcS treatment suppressed the expression of pro-inflammatory mediators interferon-gamma (IFN-γ) and nitric oxide (NO), and increased the expression of the anti-inflammatory mediator interleukin-10 (IL-10) in colon tissues, potentially as a result of altered bile acid profiles. Mechanistically, we showed that LcS treatment suppressed the activation of nuclear factor-kappa B (NF-κB) signaling <i>via</i> stabilization of inhibitor of NF-κB alpha (IκBα). Altogether, we have demonstrated the therapeutic effects of LcS in DSS-induced colitis, providing new insights into its effect on bile acid metabolism and the related anti-inflammatory mechanisms. Our findings provide support for the application of LcS in the treatment of IBD.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | probiotics, inflammatory bowel disease, Lactobacillus casei strain Shirota, gut microbiota, bile acids, DSS-induced acute colitis |
| Divisions: | Faculty of Science and Engineering > School of Electrical Engineering, Electronics and Computer Science |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 22 Jul 2022 14:09 |
| Last Modified: | 18 Oct 2023 07:08 |
| DOI: | 10.3389/fnut.2022.816836 |
| Open Access URL: | https://www.frontiersin.org/articles/10.3389/fnut.... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3159178 |
Dimensions
Dimensions
